Video

Dr. Denham on Hyperprogression in Patients With NSCLC

Author(s):

Claude Denham, MD

In Partnership With:

Claude Denham, MD, Baylor Medical Center, discusses the manifestation of hyperprogression in patients with non–small cell lung cancer (NSCLC) who have been treated with immunotherapy.

Claude Denham, MD, Baylor Medical Center, discusses the manifestation of hyperprogression in patients with non—small cell lung cancer (NSCLC) who have been treated with immunotherapy.

When asked whether there is enough research on hyperprogression in patients treated with immunotherapy to warrant concern, Denham explains that he has observed it, and that it is not fully understood by the oncology community. Denham recalled a patient in which he saw the trajectory of their cancer change markedly after their first dose of immunotherapy.

Hyperprogression in patients treated with immune agents is rare, but one of the challenges physicians have in patients with lung cancer is that many of them have a lot of smoking-related co-morbidities that make separating out the more non-specific inflammatory events of immune therapy with hyperprogression or autoimmune-related adverse events somewhat complicated.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Related Content
Ronan J. Kelly, MD, MBA, chief, oncology, Baylor Scott & White Health – North Texas; director, Baylor Scott & White Charles A. Sammons Cancer Center, Baylor University Medical Center; W.W. Caruth Jr. Endowed Chair of Immunology, Baylor University Medical Center
May 6th 2024

Agnostic Approval of Trastuzumab Deruxtecan Ushers in New Option for Advanced HER2+ Solid Tumors

Martin F. Dietrich, MD, PhD, medical oncologist, Cancer Care Centers of Brevard, The US Oncology Network, assistant professor, internal medicine, the University of Central Florida College of Medicine; Michelle Shiller, DO, cancer liaison physician, medical director, Genetics, assistant medical director, Baylor Scott & White Health in Dallas, medical director, Genomics and Molecular Pathology Services, PathGroup
June 27th 2024

Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing

Updates and Advances in Early Stage Breast Cancer
April 5th 2023

Updates and Advances in Early Stage Breast Cancer

Joyce O’Shaughnessy, MD
January 26th 2023

A Wealth of Clinical Trials Expands Potential Breast Cancer Treatment Options

Edward J. Pearson, MD
December 22nd 2022

Evolution of Targeted Therapy Improves Clinical Benefit in Blood and Bone Marrow Cancers

Manali Kamdar, MD
December 11th 2021

Dr. Kamdar on the Results of the TRANSFORM Trial in Relapsed/Refractory LBCL